Freeline Therapeutics Holdings plc

NasdaqCM:FRLN Rapport sur les actions

Capitalisation boursière : US$28.3m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Freeline Therapeutics Holdings Gestion

Gestion contrôle des critères 2/4

Freeline Therapeutics Holdings' CEO is Michael Parini, appointed in Aug 2021, has a tenure of 2.5 years. total yearly compensation is $2.16M, comprised of 27.4% salary and 72.6% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth $310.01K. The average tenure of the management team and the board of directors is 2.1 years and 4.3 years respectively.

Informations clés

Michael Parini

Directeur général

US$2.2m

Rémunération totale

Pourcentage du salaire du PDG27.4%
Durée du mandat du directeur général2.5yrs
Propriété du PDG1.1%
Durée moyenne d'occupation des postes de direction2.1yrs
Durée moyenne du mandat des membres du conseil d'administration4.3yrs

Mises à jour récentes de la gestion

Recent updates

Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

Jul 13
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Apr 11
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Dec 20
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Aug 30
We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Freeline gains as NEJM publishes long-term data for hemophilia therapy

Jul 21

Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

May 05
Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Jan 13
Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Sep 30
Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

Jun 03
Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Feb 18
What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Analyse de la rémunération des PDG

Comment la rémunération de Michael Parini a-t-elle évolué par rapport aux bénéfices de Freeline Therapeutics Holdings?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$53m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$2mUS$591k

-US$89m

Sep 30 2022n/an/a

-US$101m

Jun 30 2022n/an/a

-US$117m

Mar 31 2022n/an/a

-US$132m

Dec 31 2021US$1mUS$419k

-US$140m

Rémunération vs marché: Michael's total compensation ($USD2.16M) is above average for companies of similar size in the US market ($USD671.51K).

Rémunération et revenus: Michael's compensation has increased whilst the company is unprofitable.


PDG

Michael Parini (48 yo)

2.5yrs

Titularisation

US$2,160,000

Compensation

Mr. Michael J. Parini, JD., serves as Chief Executive Officer & Executive Director at Freeline Therapeutics Limited since August 16, 2021. He had been President and Chief Operating Officer at Freeline Ther...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Parini
CEO & Executive Director2.5yrsUS$2.16m1.1%
$ 310.0k
Paul Schneider
CFO & Director1.8yrspas de donnéespas de données
Henning Stennicke
Chief Scientific Officer1.9yrspas de donnéespas de données
Nicole Jones
Chief People Officer1.6yrspas de donnéespas de données
James Bircher
Chief Technical Operations Officer2.6yrspas de donnéespas de données
Pamela Foulds
Chief Medical Officer2.3yrspas de donnéespas de données
Naomi Aoki
Senior Vice President of Corporate Communications & Investor Relationsno datapas de donnéespas de données
Amy Spandau
Interim Head of Financeno datapas de donnéespas de données

2.1yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: FRLN's management team is considered experienced (2.1 years average tenure).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Parini
CEO & Executive Director2.5yrsUS$2.16m1.1%
$ 310.0k
Paul Schneider
CFO & Directorless than a yearpas de donnéespas de données
Julia Gregory
Independent Non-Executive Director4.3yrsUS$172.00kpas de données
Colin Love
Independent Non Executive Director2.9yrsUS$93.00kpas de données
Christopher Hollowood
Independent Chairman8.2yrsUS$93.00kpas de données
Jeffrey Chodakewitz
Independent Non-Executive Director4.5yrsUS$166.00kpas de données
Martin Andrews
Independent Non-Executive Director5.3yrsUS$154.00kpas de données

4.3yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Conseil d'administration expérimenté: FRLN's board of directors are considered experienced (4.3 years average tenure).